# The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases

> **NCT06285279** · PHASE1 · RECRUITING · sponsor: **Nanjing University School of Medicine** · enrollment: 24 (estimated)

## Conditions studied

- Lupus Nephritis
- ANCA-associated Vasculitis
- Membranous Nephropathy - PLA2R Induced
- IgG4-Related Diseases

## Interventions

- **DRUG:** FKC288

## Key facts

- **NCT ID:** NCT06285279
- **Lead sponsor:** Nanjing University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-04
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06285279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06285279, "The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT06285279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*